Revenue: As of FY2025 Q1, the actual value is USD 517 K.

EPS: As of FY2025 Q1, the actual value is USD 0.28.

Segment Revenue

• Total revenue for the first quarter of 2025 was $517,000, with $147,000 from the initial U.S. commercial launch of Symvess and $370,000 from a research collaboration.

Operational Metrics

• Cost of goods sold for the first quarter of 2025 was $147,000, with no cost of goods sold reported for the first quarter of 2024.
• Research and development expenses decreased to $15.4 million in the first quarter of 2025 from $21.3 million in the same period of 2024, primarily due to decreased materials costs and reduced clinical study costs.
• General and administrative expenses increased to $8.1 million in the first quarter of 2025 from $5.3 million in the first quarter of 2024, mainly due to the U.S. commercial launch of Symvess.
• Net income for the first quarter of 2025 was $39.1 million, compared to a net loss of $31.9 million in the first quarter of 2024, primarily due to the non-cash remeasurement of the contingent earnout liability.

Cash Flow

• The company reported cash, cash equivalents, and restricted cash of $113.2 million as of March 31, 2025.
• Total net cash provided was $17.9 million for the first three months of 2025, compared to $35.1 million for the same period in 2024, with the decrease primarily due to the absence of a $20 million funding draw that occurred in 2024.

Unique Metrics

• Humacyte completed a public offering in March 2025, raising $46.7 million in net proceeds.
• The company implemented cost reduction actions, including workforce reductions and deferred hiring, estimating net savings of approximately $13.8 million in 2025 and up to $38.0 million in 2026.

Outlook / Guidance

• Humacyte plans to continue expanding the commercial launch of Symvess and anticipates filing an Investigational New Drug (IND) application for the small-diameter ATEV in coronary artery bypass grafting later in 2025.
• The company is on track to file a supplemental Biologics License Application (BLA) for ATEV in dialysis in 2026, following a major enrollment milestone in its V012 Phase 3 trial.